J&J has a COVID-19 vaccine candidate, Phase 1 trials to start in September

Shares of Johnson & Johnson JNJ, 6.715% gained 5% in premarket trading on Monday after the company said it had identified a lead candidate in its efforts to develop a COVID-19 vaccine. J&J said Monday it plans to begin Phase 1 clinical trials of the vaccine candidate in humans in September, and the investigational vaccine may be ready for emergency use authorization from the Food and Drug Administration by early 2021.